Products for Research Use Only

Atazanavir-d5

CAT: 0804-HY-17367S3-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17367S3-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) [2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].
CAS Number
1132747-14-8
UNSPSC
12352005
Target
Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; Isotope-Labeled Compounds; P-glycoprotein; SARS-CoV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Others
Field of Research
Infection; Cancer
Solubility
10 mM in DMSO
Smiles
[2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1C[C@H](NC([C@H](C(C)(C)C)NC(OC)=O)=O)[C@@H](O)CN(NC([C@H](C(C)(C)C)NC(OC)=O)=O)CC2=CC=C(C3=CC=CC=N3)C=C2
Molecular Formula
C38H47D5N6O7
Molecular Weight
709.89
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6 (6) :785-96.|[3]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38 (11) :1599-604.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported